NIH-funded research U01 cooperative agreement

CODA-based cervical cancer screening in low-resource settings

Official title: Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach

Funded at Massachusetts General Hospital · NIH-11535357 · Data updated 2026-11-12

A new, quick, low-cost test using CRISPR and fluorescence readouts to help screen for cervical cancer in women in sub-Saharan Africa.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionMassachusetts General Hospital
NIH-funded
Lab location1 site (Boston, United States)
Project startJuly 1, 2023
Project endJune 30, 2028
Funding year2026
Award (this year)$124,465
NIH project number3U01CA279858-04S1
Project IDNIH-11535357 on NIH RePORTER

Who could benefit from this research

Could help

Women in sub-Saharan Africa who are eligible for cervical cancer screening, particularly in Uganda and Ghana.

Less likely to help

If a clinic lacks the necessary infrastructure or trained personnel, the test may not be implemented effectively.

What this research studies

This project aims to bring a fast, easy-to-use nucleic acid test to clinics in Uganda and Ghana so healthcare workers can screen women for cervical abnormalities in under 30 minutes. The test, CODA, combines CRISPR-based detection with a simple optical readout to identify DNA/RNA markers of cervical precancer, designed for low-resource settings. The team will validate the method with human specimens and adapt workflows so clinicians and lab staff can implement it in real-world clinics. The work emphasizes clinician and lab training, workflow integration, and collaboration with local partners to ensure feasibility and sustainability in LMIC environments.

Why it matters

Potential benefit: If successful, the test could enable rapid, affordable cervical cancer screening at the point of care, reducing delays and expanding access for women in LMICs.

How similar studies have gone: Preliminary data suggest CRISPR-based diagnostics can work with simple readouts, but large-scale validation in LMIC settings is needed.

Where this research is happening

  • Massachusetts General Hospital
    Boston, United States
    Active

Researchers

  • Principal investigator: Castro, Cesar M — Massachusetts General Hospital
  • Study coordinator: Castro, Cesar M

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.